12月15日 - ** Neuren Pharmaceuticals NEU.AX 股价飙升3.8%至19.73澳元，创下自12月5日以来的最大盘中涨幅** 该公司称， (link) 合作伙伴Acadia Pharmaceuticals ACAD.O获得了美国FDA对DAYBUE STIX trofinetide 口服液的批准。DAYBUE STIX(trofinetide) 的口服溶液获得美国 FDA 批准** DAYBUE STIX 是一种粉末配方，用于治疗雷特综合症（一种影响大脑发育的罕见遗传性疾病）** 公司获得净销售额的特许权使用费** 截至目前，公司股价上涨了 57.6%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.